Avoiding Qui Tam Lawsuits by Properly Handling Disgruntled Employees

There Are a Number of Ways that Providers Can Mitigate Risk

Jesse A. Witten and Patrick H. Thompson

The greatest compliance enforcement risk facing health care providers is the risk of a lawsuit filed under the qui tam provisions of the False Claims Act (FCA). Disgruntled employees or former employees often file qui tam lawsuits to get even for the wrongs they believe they have suffered or are experiencing at work, through qui tam allegations that are frequently unrelated to their workplace issues. Accordingly, the malcontent employee must be understood as posing potential risk to an organization over and above a traditional human resources challenge. Properly handling such an employee can mean the difference between enabling the provider to remediate a regulatory issue internally and spending millions of dollars on legal fees, and potentially penalties and fines.

The Risk from Whistleblowers

The FCA is the federal government’s principal tool for fighting fraud, including Medicare and Medicaid fraud. A provider that submits or causes to be submitted a “false or fraudulent claim” to Medicare, Medicaid, or other federal health programs can be liable for treble damages plus penalties of $5,500 to $11,000 for every false claim. In addition, since enactment of the Affordable Care Act, the FCA imposes liability on a provider that fails to report and refund a Medicare overpayment within 60 days of identifying it. Under the qui tam provisions of the FCA, private individuals known as “relators” can file suit on behalf of the government and on their own behalf, accusing the defendant of defrauding the government. Employees and former employees are the most common relators. After a relator files a qui tam complaint under seal, the government has a period of time to investigate and decide whether to intervene and take over the litigation. If the government intervenes, the relator gets to keep 15 to 25 percent of whatever the government eventually
recover through settlement or at trial. If the government declines to intervene, the relator can still litigate the action on behalf of the government and is entitled to keep 25 to 30 percent of any eventual recovery.

Most of the government’s recovery under the FCA comes from cases originally filed by relators under the FCA. For instance, according to U.S. Department of Justice statistics, in 2012 and 2013, of the $8.74 billion recovered by the government under the FCA, $6.31 billion (or 72 percent) came from cases initially filed by relators. In health care fraud cases during the same two years, of the $5.76 billion recovered $5.14 billion (or 89 percent) came from cases originally filed by relators.

The number of qui tam suits filed has approximately doubled since 2007, rising from 365 new matters in 2007 to over 700 per year in 2013 and 2014. From 2007 through 2013, 3,791 qui tam suits were filed, with 2,424 alleging health care fraud. In 2013, relators brought 753 qui tam actions, of which 500 alleged health care fraud.1

The risk of qui tam lawsuits promises to increase, due in part to the following developments:

■ The Obama Administration has made combating health care fraud a top priority, increasing government resources to support FCA litigation and raising awareness among the public and plaintiffs’ attorneys of the qui tam provisions.

■ The Affordable Care Act has increased FCA liability to providers in a variety of ways, including (as noted above) imposing liability on the knowing failure to refund Medicare overpayments within 60 days.

■ Under federal law, health care providers that receive at least $5 million in annual Medicaid reimbursement are required to provide “detailed information” to their employees on the qui tam provisions of the FCA.

■ An increasing number of states and local governments have enacted their own versions of the FCA, including qui tam provisions. There are currently 24 states and the District of Columbia with their own FCAs, as well as New York City and Chicago.

CHANNELING WOULD-BE RELATORS INTO THE COMPLIANCE PROGRAM

A provider’s primary objective should be to channel potential whistleblowers through the provider’s compliance program. Most importantly, this gives the provider an opportunity to address legitimate concerns and improve compliance. This also makes best use of employees who might otherwise file qui tam lawsuits because they are genuinely frustrated by what they perceive to be regulatory noncompliance and a lack of an adequate response on the part of their employer. For these employees, an effective compliance program and appropriate feedback to the employee after a regulatory concern is raised can be effective.

Other employees, however, file qui tam lawsuits for more pernicious reasons, i.e., because they want to make money, they are seeking revenge, or they have some other personal motivation. Because the qui tam provisions can trigger the worst in some employees, some strategic work is necessary. To channel these employees through the compliance department, health care providers should require all employees to report regulatory violations internally. Employees should be encouraged to report in the first instance to their supervisor but be directed to report to the Compliance Department if they prefer or if they are not satisfied with how the supervisor has responded. Providers should give employees notice that the failure to report a regulatory violation of which they are aware can lead to disciplinary action. At the same time, however, employees also should be assured that good faith internal reports will not lead to retaliation against them. These reporting policies should be included in an employee handbook and/or in the compliance program materials.

Some health care providers and other entities require a subgroup of management-level employees to certify annually that they
Avoiding *Qui Tam* Lawsuits

are not aware of any compliance problems or to identify any issues about which they are concerned. If an employer adopts this approach, the certification should not be phrased in a leading manner. For instance, it should not state: “I hereby certify that I am aware of no regulatory violations.” Rather, the certification should be open-ended and drafted in a manner that facilitates disclosure.

When employers do learn of an employee’s concern about a regulatory issue, it is important to investigate fully and then take appropriate remedial steps, if necessary. The first step is to obtain a complete account from the employee. Two people should conduct the interview so that there are at least two witnesses who can attest to what the employee said. If the interview is conducted by an attorney, it will be important to advise the employee that the conversation will be covered by the employer’s attorney-client privilege, and the employee is not authorized to disclose the content of that communication outside the company.

The employee should be sufficiently informed regarding what the employer is doing to investigate the employee’s expressed concerns about regulatory noncompliance to understand that the employer is making a good faith response. That does not mean that the employer must reveal all facts to the employee or inform the employee of all investigative measures. How much information should be shared depends on the nature of the complaint and, importantly, on the employee.

Upon conclusion of an investigation, employees must be informed of the ultimate resolution. Again, how to provide that information will vary from one situation to another. In some cases, it may be appropriate to permit the employee to read a final investigative report while in other cases an oral report may be more appropriate. In any event, it is important to demonstrate to the would-be whistleblower that the investigation and decision regarding remedial action were taken in good faith.

Many *qui tam* actions, including some that have resulted in multi-million dollar settlements, could have been deterred had the provider given the disgruntled employee ongoing feedback during the compliance investigation and briefed the employee on the general results of the investigation, and the company’s response and rationale.

**Reassignment**

Sometimes, reassigning an employee viewed as a potential whistleblower from one position to another is appropriate. For example, reassignment can be a good option if the employee is uncomfortable with acting in accordance with the employer’s regulatory interpretation, though the employee agrees that the employer’s position is reasonable. On other occasions, an employee’s complaint may in fact be a veiled plea for reassignment, and some flexibility in providing the reassignment may be called for.

Any decision to reassign an employee must be taken with care, however, and ideally with the employee’s consent. An unwelcome reassignment can subject the employer to an accusation that it has retaliated against the employee. The federal False Claims Act and many state laws prohibit retaliation against employees for raising certain compliance issues. For example, federal law gives employees a right of action against their employer for retaliating against them for taking action to prevent a violation of the False Claims Act.

**Departing Employees and Severance Agreements**

Exit interviews with departing employees can be effective opportunities to learn of an employee’s compliance concerns. Unfortunately, these interviews often are not conducted or the health care provider fails to ask the departing employee whether he or she had any compliance concerns. It is important, however, to ask these questions of departing employees. An employee who intends to file a *qui tam* lawsuit might not volunteer his or her compliance concerns, but by asking the
question and documenting the lack of a response, the employer may help itself in its future defense.

When a health care provider elects to enter into a severance agreement with a departing employee, there are a number of provisions that should be included in the agreement but which are frequently omitted. These provisions can smoke out the departing employee’s compliance concerns and give the employer the opportunity to act upon them. This can either deter the employee from filing a *qui tam* action or, if the employee does file suit, it can help the employer in its defense.

First, the severance agreement should require the employee to represent that he or she has or will disclose all regulatory violations of which the employee is aware. This provision could state, for instance:

Employee hereby represents and warrants that [in his memorandum to Jane Roe dated MM/DD/YYYY] [during his exit interview on MM/DD/YYYY with PERSON 1 and PERSON 2], he informed XYZ Health System of all potential regulatory violations by any of the Released Parties, and of all potential overpayments received by any of the Released Parties from Medicare, Medicaid or other third-party payors, of which he is aware.

If the employee claims not to be aware of any regulatory violations, the severance agreement should contain a representation to that effect.

Second, the severance agreement should require the employee to refund all severance payments if he or she has or will disclose any regulatory violations of which the employee is aware. This provision could state, for instance:

If Employee breaches any of the terms of this Agreement, he shall be liable to XYZ Health System for the Settlement Amount in addition to any other remedies available to XYZ under law or equity.²

This provision, along with the first provision, would not preclude an employee from filing a *qui tam* action, but if the employee files suit on the basis of an undisclosed regulatory violation or overpayment, the employee will likely be liable to repay the severance payment.

Third, the severance agreement should contain a broad release, broad enough to cover a *qui tam* action. The courts have reached differing conclusions as to whether a release of a *qui tam* action is enforceable. The majority of courts have held that releases in severance agreements provide an enforceable defense to a *qui tam* action if the government already had knowledge of the allegations and had an opportunity to investigate them prior to the date of the release.³ A broad release of all claims should be sufficient, if the court is willing to enforce a release in the *qui tam* context. Including an express release of the employee’s rights under the *qui tam* provisions could backfire and be portrayed as an effort to obstruct justice.

Finally, in some cases, it may be advisable to include a clause in the severance agreement that requires the departing employee to assist with the employer’s ongoing investigation. This could require the payment of additional compensation to the departing employee, however, at a time when the employer wants to terminate all ties to a troublemaking employee.

**Non-disparagement and Confidentiality Policies in Severance Agreements**

An emerging issue to consider is the inclusion of a non-disparagement or confidentiality provision in a severance agreement. These sorts of provisions — in which both the employer and employee agree not to make negative comments about the other in any statement made to a third party — are common in employee severance agreements.

Government contractors and health care providers, however, should take care before
including these provisions in severance agreements. If the non-disparagement provision is worded broadly enough so that it could be viewed as preventing an employee from disclosing regulatory violations to the government, the government could accuse the employer of making a “hush” payment. This is an emerging issue that has not received much attention until recently, largely spurred by the U.S. Securities and Exchange Commission’s (SEC) recent enforcement action against KBR, Inc.

In April 2015, the SEC charged KBR with violating securities laws by requiring witnesses in certain internal investigations to sign confidentiality statements with language warning that they could face discipline and even be fired if they discussed the matters with outside parties without the prior approval of the company’s legal department. KBR settled the SEC’s charges for $130,000. Announcing the settlement, the director of the SEC’s Division of Enforcement stated, “SEC rules prohibit employers from taking measures through confidentiality, employment, severance, or other type of agreements that may silence potential whistleblowers before they can reach out to the SEC. We will vigorously enforce this provision.”

Although the KBR matter was enforced as an SEC regulatory issue, some have expressed concern that other federal laws also may bar non-disparagement or confidentiality provisions that restrain an employee or former employee from informing the government of concerns over regulatory violations. The greatest concern is that an employer could be accused of obstruction of justice, or the non-disparagement provision could be held against the employer in the event of a future False Claims Act investigation or other enforcement action. Accordingly, health care providers should carefully consider the precise language of any non-disparagement provisions included in a severance agreement.

**Conclusion**

Health care providers face a substantial risk that a disgruntled employee or former employee will file a *qui tam* action. There are a number of ways that providers can mitigate that risk, such as by implementing procedures intended to channel regulatory complaints through the provider’s compliance program. In addition, when the provider elects to enter into a severance agreement, the provider should insist on including certain provisions that can reduce the risk of a *qui tam* action.

**Endnotes:**

2. If the severance agreement also requires the employee to waive any claims under the Age Discrimination in Employment Act (ADEA), the refund of all severance payments must be coordinated with the EEOC’s requirements for lawful ADEA waivers.
5. Id.